Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a China-based company principally engaged in the research, development, manufacturing and retail of Chinese herbal medicines, Chinese patent medicines, chemical raw materials and preparations, and nutritional health products. The Company operates its businesses through three segments. The Chinese Patent Medicine segment is mainly engaged in the research, development, manufacturing and sales of Chinese medicines, including Su Xiao Jiu Xin Pill, Jing Wan Hong Ruan Gao, An Gong Niu Huang Pill, Qing Gong Shou Tao Pill and other products. The Western Medicine segment is mainly engaged in the research, development, manufacturing and sales of Western medicines. The Others segment mainly includes economic information consulting services, house leasing and other businesses. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,890

Sector

Pharmaceuticals

Calendar

10-31 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-30	CN¥35.32	+2.08%	1,995,302
26-09-29	CN¥34.60	-1.65%	1,557,304

End-of-day quote Shanghai S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.32

Average target price

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. 2026-09-30			5-day change	1st Jan Change
35.32 ^CNY	+2.08%		+0.40%	-22.58%

09-25	Tianjin Pharmaceutical Lists Proposed 100% Upstream Stake Transfer for Tender	MT
09-04	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Appointment of Chen Hong as General Manager	CI

Market Cap	23.53B 3.51B 3.13B 2.92B 2.65B 5B 338B 5.04B 35.24B 13.71B 172B 13.17B 12.89B 554B	P/E 2026 *	26.4x	P/E 2027 *	22.9x
Enterprise Value	23.53B 3.51B 3.13B 2.92B 2.65B 5B 338B 5.04B 35.24B 13.71B 172B 13.17B 12.89B 554B	EV / Sales 2026 *	4.77x	EV / Sales 2027 *	4.4x
Free-Float	31.71%	Yield 2026 *	-	Yield 2027 *	-

09-25	Tianjin Pharmaceutical Lists Proposed 100% Upstream Stake Transfer for Tender	MT
09-04	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Appointment of Chen Hong as General Manager	CI
08-14	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-10	Tianjin Pharmaceutical Gets China Nod for Diabetes Combo Drug	MT
08-10	Tianjin Pharmaceutical Signs 113-Million-Yuan Distribution Deal	MT
08-09	Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration	MT
08-09	Tianjin Pharmaceutical Da Ren Tang to Sign Warehousing Deal	MT
08-07	Xinxin Pharmaceutical Plant Receives Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Sustained-Release Tablets (I)	CI
08-07	Tianjin Pharmaceutical Da Ren Tang Secures China Nod for Diabetes Combo Drug	MT
07-14	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026	CI
07-14	Tianjin Pharmaceuticals Warns of Up to 68% Plunge in H1 Profit	MT
06-25	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Adjustments to the Composition of the Respective Board Committees	CI
05-20	Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender	MT

24-09-30	Borsa di Italia: nuovi fuochi d'artificio sul mercato azionario cinese
24-09-30	Bolsa de Madrid: Nuevos fuegos artificiales bursátiles en China
24-09-30	En direct des marchés : Stellantis avertit, Volkswagen avertit, Aston Martin avertit
24-09-30	Nouveau feu d'artifice boursier en Chine

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Stock

Stocks

600329

CNE000001808

Pharmaceuticals

Valuation: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Chart: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Latest news: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Press Releases: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

News in other languages: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Latest insider transactions

Alternative Medicine

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 day	+2.08%
1 week	+0.40%
1 month	-1.78%
3 months	-11.63%
6 months	-14.06%
Current year	-22.58%

1 week	34.61	35.43
1 month	33.83	36.17
Current year	33.83	48.2
1 year	33.83	50.95
3 years	23.4	50.97
5 years	17.98	56.26
10 years	11.8	56.26

Manager	Title	Age	Since
Hong Chen CEO	Chief Executive Officer	56	2026-09-03
Hong Zhou PRN	Corporate Officer/Principal	56	-
Mai Wang PRN	Corporate Officer/Principal	56	-

Director	Title	Age	Since
Xiu Mei Guo BRD	Director/Board Member	44	2018-12-23
Mai Wang BRD	Director/Board Member	56	-
Hong Zhou BRD	Director/Board Member	56	2019-05-14

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/20	Yan Jiao	Buy	Company Secretary	30,000	0.0053%
1/8/20	Hong Zhou	Buy	Chief Technology Officer	70,000	0.0124%
1/8/20	Hong Yu	Buy		70,000	0.0124%

	2026 *	2027 *
Net sales	4.93B 735M 656M 611M 556M 1.05B 70.83B 1.06B 7.39B 2.87B 36.15B 2.76B 2.7B 116B	5.35B 798M 712M 663M 604M 1.14B 76.86B 1.15B 8.02B 3.12B 39.23B 3B 2.93B 126B
Net income	1.04B 155M 138M 128M 117M 220M 14.88B 222M 1.55B 604M 7.6B 580M 568M 24.41B	1.18B 177M 158M 147M 134M 252M 17.01B 253M 1.77B 690M 8.68B 663M 649M 27.9B
Net Debt	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.08%	+0.40%	-18.52%	-3.05%	3.5B
ELI LILLY AND COMPANY	+0.02%	-3.52%	+36.11%	+111.11%	1,019B
JOHNSON & JOHNSON	-1.21%	-6.99%	+34.08%	+60.96%	617B
ABBVIE INC.	+1.12%	-0.20%	+13.62%	+80.24%	464B
MERCK & CO., INC.	-3.30%	-6.15%	+56.45%	+34.69%	356B
ROCHE HOLDING AG	+0.93%	-1.83%	+21.65%	+41.43%	333B
NOVARTIS AG	+0.12%	-4.05%	+10.70%	+33.53%	267B
ASTRAZENECA PLC	-0.89%	-5.83%	-7.00%	+7.91%	244B
AMGEN INC.	-0.01%	-3.62%	+35.28%	+52.02%	218B
GILEAD SCIENCES, INC.	-0.08%	-4.98%	+28.34%	+93.61%	179B
Average	+0.40%	-3.39%	+21.07%	+51.25%	370.07B
Weighted average by Cap.	+0.45%	-3.63%	+28.46%	+68.43%